ijms-logo

Journal Browser

Journal Browser

Integrated Approaches, Molecular Mechanism and Therapies in Ocular Surface Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 September 2025 | Viewed by 1467

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medicine and Surgery, University of Enna “Kore”, Piazza dell'Università, 94100 Enna (EN), Italy
Interests: glaucoma; clinical ophthalmology; retinal diseases; inflammation; immunology of infectious diseases; OCT; macular degeneration; eye diseases; corneal diseases; ocular surface; dry eye diseases; retinal degeneration; inherited retinal disorders; rare ophthalmic diseases

E-Mail Website
Guest Editor
Department of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy
Interests: clinical ophthalmology; glaucoma; tonometry; ocular hypertension; visual field testing; OCT; pachymetry; refractive errors; cornea; dry eye disorders; stem cells; corneal wound lesions; ocular surface; lid diagnostics and treatments
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Eye Clinic, Public Health Department, University of Naples Federico II, 80131 Naples, Italy
Interests: cataract surgery; ocular trauma management; vitreoretinal surgery; experimental ocular surgery; 3D surgery; secondary IOL implantation; pole-to-pole surgery

Special Issue Information

Dear Colleagues,

We are pleased to host a Special Issue entitled “Integrated Approaches, Molecular Mechanism and Therapies in Ocular Surface Diseases”. This Special Issue seeks to investigate the novel applications of blood-derived products in the treatment and management of ocular surface diseases. We welcome submissions from top scholars, clinicians, and healthcare professionals who are pioneers in their fields. This issue will cover a wide range of topics, including the molecular and cellular mechanisms, clinical applications, and outcomes of using autologous serum, platelet-rich plasma, umbilical cord derivatives, and other novel blood-based therapies to treat conditions such as dry eye syndrome, corneal ulcers, and persistent epithelial defects.

Our goal is to create a complete collection of original research articles, reviews, and case studies that demonstrate the efficacy and safety of these treatments, as well as their integration into established therapy procedures. This special issue aims to expand our understanding and application of blood component therapy in ophthalmology by bringing together varied perspectives and discoveries. In addition, our goal is to explore the molecular processes by which these medicines are derived from blood exercise and their effects on illnesses of the ocular surface. This Special Issue will enhance our comprehension of how these medicines might be optimized for clinical use by examining the fundamental biological processes and their therapeutic consequences.

We welcome papers that shed light on patient selection, treatment methods, and long-term outcomes, as well as those that investigate the molecular mechanisms underlying the healing benefits of these therapies. This is a great opportunity to contribute to a growing field of study with important clinical consequences, and we look forward to receiving your valuable submissions.

Prof. Dr. Caterina Gagliano
Dr. Marco Zeppieri
Prof. Dr. Mario Damiano Toro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Keywords

  • ocular surface diseases
  • dry eye
  • corneal ulcers
  • persistent epithelial defects
  • blood-derived products
  • blood-based therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

22 pages, 6428 KiB  
Article
Rebamipide Enhances Pathogen Defense and Mitigates Inflammation in a Particulate Matter-Induced Ocular Surface Inflammation Rat Model
by Basanta Bhujel, Se-Heon Oh, Woojune Hur, Seorin Lee, Hun Lee, Ho-Seok Chung and Jae Yong Kim
Int. J. Mol. Sci. 2025, 26(8), 3922; https://doi.org/10.3390/ijms26083922 - 21 Apr 2025
Viewed by 232
Abstract
Particulate matter (PM) exposure is known to induce significant ocular surface inflammation, necessitating effective therapeutic interventions. This study compared the efficacy of 2% rebamipide (REB) with 0.1% hyaluronic acid (HA) eye drops in investigating the anti-inflammatory and pathogen-clearance effects in a PM-induced ocular [...] Read more.
Particulate matter (PM) exposure is known to induce significant ocular surface inflammation, necessitating effective therapeutic interventions. This study compared the efficacy of 2% rebamipide (REB) with 0.1% hyaluronic acid (HA) eye drops in investigating the anti-inflammatory and pathogen-clearance effects in a PM-induced ocular surface inflammation model using Sprague–Dawley (SD) rats. Parameters including clinical signs, histological changes, mucin secretions, inflammatory cytokines, mast cell degranulation, dysregulated cell proliferation, and cellular apoptosis were evaluated. 2% REB alleviated ocular surface inflammation by downregulating the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inflammatory pathway and upregulating epidermal growth factor receptor (EGFR) signaling, thereby enhancing mucin secretion and promoting pathogen clearance. Histopathological analysis, western blot, and immunohistochemical staining revealed a marked reduction in inflammatory markers including MMP-9, IL-1β, TNF-α, IL-17, and CD-4, decreased mast cell degranulation, increased goblet cell density, and enhanced expression of mucins, including MUC5AC and MUC16, in the 2% REB-treated group compared to the 0.1% HA-treated and PM-exposed groups. Moreover, 2% REB demonstrated decreased apoptosis (TUNEL) and reduced uncontrolled cell proliferation (Ki67), indicating improved cellular integrity. In conclusion, 2% REB is a promising treatment option for PM-induced ocular surface inflammation in a rat model compared with 0.1% HA, offering the benefits of reducing inflammation, clearing pathogens, and protecting overall ocular health. Full article
Show Figures

Graphical abstract

Review

Jump to: Research

23 pages, 16541 KiB  
Review
Adhesion Mechanism, Applications, and Challenges of Ocular Tissue Adhesives
by Zuquan Hu, Xinyuan He, Lijing Teng, Xiangyu Zeng, Simian Zhu, Yu Dong, Zhu Zeng, Qiang Zheng and Xiaomin Sun
Int. J. Mol. Sci. 2025, 26(2), 486; https://doi.org/10.3390/ijms26020486 - 8 Jan 2025
Viewed by 1092
Abstract
Corneal injury is prevalent in ophthalmology, with mild cases impacting vision and severe cases potentially resulting in permanent blindness. In clinical practice, standard treatments for corneal injury involve transplantation surgery combined with pharmacological therapy. However, surgical sutures exhibit several limitations, which can be [...] Read more.
Corneal injury is prevalent in ophthalmology, with mild cases impacting vision and severe cases potentially resulting in permanent blindness. In clinical practice, standard treatments for corneal injury involve transplantation surgery combined with pharmacological therapy. However, surgical sutures exhibit several limitations, which can be overcome using tissue adhesives. With recent advances in biomedical materials, the use of ophthalmic tissue adhesives has expanded beyond wound closure, including tissue filling and drug delivery. Furthermore, the use of tissue adhesives has demonstrated promising outcomes in drug delivery, ophthalmic disease diagnosis, and biological scaffolds. This study briefly introduces common adhesion mechanisms and their applications in ophthalmology, aiming to increase interest in tissue adhesives and clinical ophthalmic treatment. Full article
Show Figures

Figure 1

Back to TopTop